Skip to main content
    M

    Mirum Pharmaceuticals Inc (MIRM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $91.58
    -2.41 (-2.56%)

    Market Cap: $6.14B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Mirum Pharmaceuticals Inc (MIRM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Mirum Pharmaceuticals (MIRM) to earn -$15.67 per share in the fiscal year ending Dec 31, 2026, on revenue of $717.61M. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.32.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.71, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy428.6%
    Buy1071.4%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 21.0%.

    Fiscal year ending Dec 31, 2026
    -$15.67
    EPS consensus, revenue $717.61M
    Fiscal year ending Dec 31, 2027
    $0.32
    EPS consensus, revenue $868.56M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$15.67-$15.67 to -$15.671$717.61M$715.00M to $719.90M11
    Dec 31, 2027$0.32$0.32 to $0.321$868.56M$791.60M to $948.17M12

    Quarterly Estimates

    The EPS consensus falls from -$0.59 for the quarter ending Dec 31, 2026 to -$0.67 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.59-$1.15 to -$0.1215$198.00M$178.36M to $207.42M14
    Mar 31, 2027-$0.67-$0.97 to -$0.437$198.68M$188.36M to $210.60M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202600
    Fiscal year ending Dec 31, 202701
    Quarter ending Mar 31, 202721

    EPS Trend

    Over the last 60 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$15.14.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$15.67-$15.23-$15.14-$15.14N/AN/A
    Fiscal year ending Dec 31, 2027$0.32-$0.71-$0.35-$0.35-$0.04N/A
    Quarter ending Mar 31, 2027-$0.67-$0.33-$0.33-$0.33-$0.34N/A

    Frequently Asked Questions About MIRM

    What is the MIRM stock forecast?

    Consensus analyst estimates put Mirum Pharmaceuticals's EPS at -$15.67 for the fiscal year ending Dec 31, 2026, on revenue of $717.61M. The consensus rating from 14 analysts is Buy.

    How do analysts rate MIRM stock?

    Of 14 analysts covering Mirum Pharmaceuticals, 4 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from MIRM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$15.67, with estimates from -$15.67 to -$15.67 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.32, with estimates from $0.32 to $0.32 from 1 analyst.

    What revenue do analysts expect from Mirum Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $717.61M, with estimates from $715.00M to $719.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $868.56M, with estimates from $791.60M to $948.17M.

    How many analysts cover MIRM?

    14 analysts rate Mirum Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.